by Rod Raynovich | May 31, 2011 | BIOgraph
Despite the continuing gloomy backdrop of a Greece default, U.S, debt ceiling and weak housing data, several market sectors rallied today. The NASDAQ was the leader up 1.37% and the S&P was up 1.06%. Energy was the sector leader up 1.39% helped by higher crude...
by Rod Raynovich | May 31, 2011 | 2023-24 Life Science Portfolios, BIOgraph
The life science market continued to show resilience today with a few big movers and a bidding up of large cap drugs such as Johnson and Johnson (JNJ $67.15), Novartis (NVS $64.24), Pfizer(PFE $21.21) and Sanofi-Aventis (SNY $39.42). Foreign drug companies fared...
by Rod Raynovich | May 27, 2011 | BIOgraph
This is a continuation of pre-ASCO coverage, reviewing companies that will have significant clinical presentations on cancer products in their pipeline. Incyte Corporation (INCY $17.82) up 1.94%. is focused on small molecule drugs for hematological and oncology...
by Rod Raynovich | May 27, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Our recent article on biotech investing and ETF’s in general are posted on Investor Uprising. Note to get the article on the right side of the page you need to register at no charge for Investor Uprising. Investor Uprising – IU Education – Guide to...
by Rod Raynovich | May 26, 2011 | BIOgraph
Here is a brief review of stocks to watch with potential ASCO impact although it is likely that prices already reflect the scientific news: Ariad Pharmaceuticals Inc. (ARIA $8.43) up 0.36% will present Phase III data on ponatinab, its investigational pan-BCR-ABL and...
by Rod Raynovich | May 25, 2011 | 2023-24 Life Science Portfolios, BIOgraph
A bull market in life science stocks has revved up news for the upcoming ASCO Meeting on June 3 in Chicago. We will provide limited coverage of stocks to watch and scientific articles of interest. However it is clear that many PR shops and newsletters are busy...
by Rod Raynovich | May 24, 2011 | BIOgraph
The Life Science market consolidation trend continued today as Nestle SA acquires privately held Prometheus Laboratories, Inc. of San Diego,CA for about $567M according to a Bloomberg story although the price was not disclosed. Other stories put the price closer to...
by Rod Raynovich | May 23, 2011 | 2023-24 Life Science Portfolios, BIOgraph
It was a nasty day from the beginning but losses abated as the day wore on. The NASDAQ was off 1.68%, the Dow down 1.05% and the S&P down 1.15% to 1317. The S&P held trend lines in the 1312-1315 range. Biotech ETF’s were also losers IBB off 1.5%, FBT off...
by Rod Raynovich | May 20, 2011 | 2023-24 Life Science Portfolios, BIOgraph
The pre-ASCO hype has already begun but many biopharma stocks have already run up 15%+ YTD. So it is time to be cautious as there may be an “ASCO Effect”- a sell on the news effect. Despite a weak tape in the major indices the life science sector has a lot...
by Rod Raynovich | May 19, 2011 | 2023-24 Life Science Portfolios, BIOgraph
M&A Premium Rocks On In a flat life science market eclipsed by the LinkedIn (LNKD) IPO and its day trading frenzy, many life science stocks in the Rayno Life Science Portfolio logged decent gains. As reported earlier today GenProbe(GPRO) sold off down 4.37% but it...